Login Register Cart 0
Generic placeholder image

Coronaviruses

Editor-in-Chief

ISSN (Print): 2666-7967
ISSN (Online): 2666-7975

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Review Article

Impact on Pharmaceutical Industry due to Sudden Pandemic Attack (COVID-19)

Author(s): Sudhanshu Mishra, Disha Sharma, Shobhit Prakash Srivastava, Swati Verma and Rishabha Malviya*

Volume 3, Issue 2, 2022

Published on: 22 December, 2021

Article ID: e280122198187 Pages: 6

DOI: 10.2174/2666796702666211122152928

Abstract

The coronavirus disease (COVID-19) was first detected in Wuhan, China, in the month of December 2019. Further, in March 2020, the COVID-19 epidemic was described by the World Health Organisation (WHO) as a global pandemic. COVID-19 quickly spread around the world in the following months, affecting about 2.5 million individuals by April 2020. World markets, including the pharmaceutical industry, were devastated by this pandemic. Although no specific solution for this emerging infectious disease is currently available, the pharmaceutical industry is helping policymakers meet unmet COVID-19 desires, ranging from research and advancement initiatives on possible prevention methods to the management of the supply chain of drugs in times of crisis. Changes in demand, commodity shortages, contact adjustments, etc., are hindering developments in the mechanism of technology, research and development and are putting an impact on the health market of COVID-19. Other implications of COVID-19 on the physical condition and pharmaceutical market may include acceptance delays, heading to self-sufficiency in the delivery chain, etc. In addition, the pharmaceutical markets are battling to sustain natural consumer flows, as the latest pandemic has had an effect on access to essential drugs at reasonable rates, which is the key priority of all pharmaceutical systems.

Keywords: COVID-19, pharmaceutical industry, financial, pharmaceutical technology, pharmaceutical market, pandemic attack.

Graphical Abstract

[1]
Elbeddini A, Prabaharan T, Almasalkhi S, Tran C. Pharmacists and COVID-19. J Pharm Policy Pract 2020; 13: 36.
[http://dx.doi.org/10.1186/s40545-020-00241-3] [PMID: 32837194]
[2]
Willan J, King AJ, Jeffery K, Bienz N. Challenges for NHS hospitals during COVID-19 epidemic. BMJ 2020; 368: m1117.
[http://dx.doi.org/10.1136/bmj.m1117] [PMID: 32198166]
[3]
Todd A, Copeland A, Husband A, Kasim A, Bambra C. The positive pharmacy care law: An area-level analysis of the relationship between community pharmacy distribution, urbanity and social deprivation in England. BMJ Open 2014; 4(8): e005764.
[http://dx.doi.org/10.1136/bmjopen-2014-005764] [PMID: 25116456]
[4]
International Pharmaceutical Federation (FIP Health Advisory). Coronavirus 2019- nCoV Outbreak. Information and interim guidelines for pharmacists and the pharmacy workforce, The Netherlands 2020 2020. Available from: https://www.fip.org/files/ content/priority-areas/coronavirus/Coronavirus-guidance-update-ENGLISH.pdf
[5]
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020; 395(10229): 1054-62.
[http://dx.doi.org/10.1016/S0140-6736(20)30566-3] [PMID: 32171076]
[6]
Sharma A, Malviya R. Effects of corona virus on the skin: Symptoms and risks. Open Dermatol J 2020; 14: 28-30.
[http://dx.doi.org/10.2174/1874372202014010028]
[7]
International Pharmaceutical Federation. Coronavirus sars-cov-2/covid-19 pandemic. Information and interim guidelines for pharmacists and the pharmacy workforce 2020. Available from: https://www.fip.org/files/content/priority-areas/coronavirus/ Coronavirus-guidance-update-ENGLISH.pdf
[8]
Song Z, Hu Y, Zheng S, Yang L, Zhao R. Hospital pharmacists’ pharmaceutical care for hospitalized patients with COVID-19: Recommendations and guidance from clinical experience. Res Social Adm Pharm 2021; 17(1): 2027-31.
[http://dx.doi.org/10.1016/j.sapharm.2020.03.027] [PMID: 32273253]
[9]
Colbourn T. COVID-19: extending or relaxing distancing control measures. Lancet Public Health 2020; 5(5): e236-7.
[http://dx.doi.org/10.1016/S2468-2667(20)30072-4] [PMID: 32220654]
[10]
Drug shortages root causes and potential solutions. US FDA 2020. Available from: https://www.fda.gov/drugs/drug-shortages/report- drug-shortages-root-causes-and-potential-solutions. (accessed on: April 13, 2020).
[11]
Current and Resolved Drug Shortages and Discontinuations Reported to FDA. FDA Drug shortages, US FDA 2020. Available from: https://www.accessdata.fda.gov/scripts/drugshortages/ (accessed on: April 02, 2021).
[12]
Current Drug Shortages. ASHP. 2020. Available from: https://www.ashp.org/drug-shortages/current-shortages?loginreturnUrl=SSOCheckOnly (accessed on: April 06, 2021).
[13]
Shifts in Healthcare Demand, Delivery and care during the COVID-19 Era. Insights, The IQVIA Institute. In: Available from: https://www.iqvia.com/insights/the-iqvia-institute/covid-19/shifts-in-healthcare-demand-delivery-and-care-during-the- covid-19-era (accessed on: April 29, 2020).
[14]
Mishra S, Sharma D, Raghuvanshi A, Rajput A, Chaturvedi V, Kumari S. Potential impact of nutrition on immune system: Prevent or assist COVID-19 recovery. JAMMR 2020; 32(22): 20-33.
[http://dx.doi.org/10.9734/jammr/2020/v32i2230702]
[15]
Panic buying amid coronavirus lockdown helped pharma market grow. Title of subordinate document 2021. Available from: https://www.business-standard.com/article/companies/panic-buying-amid-coronavirus-lockdown-helped-pharma-market- grow-9-120040801570_1.html
[16]
Panic buying amid coronavirus lockdown helped pharma market grow. Title of subordinate document 2021. Available from: https://www.business-standard.com/article/companies/panic-buying-amid-coronavirus-lockdown-helped-pharma-market- grow-9120040801570_1.html
[17]
Marsh T. Live updates: How is covid-19 affecting prescription fills?. Title of subordinate document 2021. Available from: https://www.goodrx.com/blog/medication-fills-rise-during-coronavirus-covid-19-pandemic/
[18]
Ensuring continued access to medicines during the covid-19 pandemic. Title of subordinate document 2021. Available from: https://www.health.gov.au/ministers/the-hon-greg-hunt-mp/media/ensuring-continued-access-to-medicines-during-the-covid-19-pandemic
[19]
German federal institute for drugs and medical devices. Title of subordinate document 2021. Available from: https://www.bfarm.de/EN/Drugs/licensing/amInformationen/_node.html
[20]
COVID-19 and its impact on India pharma inc. Title of subordinate document 2021. Available from: https://www.expresspharma.in/latest-updates/covid-19-and-its-impact-on-india-pharma-inc/
[21]
Aitken M, Kleinrock M. shifts in healthcare demand, delivery and care during the COVID-19 era. Title of subordinate document 2021. Available from: https://www.iqvia.com/insights/the-iqvia-institute/covid-19/shifts-in-healthcare-demand-delivery-and-care- during-the-covid-19-era
[22]
Ayati N, Saiyarsarai P, Nikfar S. Short and long term impacts of COVID-19 on the pharmaceutical sector. Daru 2020; 28(2): 799-805.
[http://dx.doi.org/10.1007/s40199-020-00358-5] [PMID: 32617864]
[23]
Pharma companies feel the pain as prices of key inputs shoot up.. The economic times 2021. Available from: https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/covid-19-impact-pharma-companies-feelthe- pain-as-prices-of-key-inputs-shoot up/articleshow/74144044
[24]
Dr Ural. Evaluating pharma amid covid-19. Title of subordinate document 2021. Available from: https://www.contractpharma.com/contents/view_online-exclusives/2020-05-18/evaluating-pharma-amidcovid-19/
[25]
The impact of COVID-19 on Middle-East healthcare: Current and future. IQVIA Webinar 2020.
[26]
Monitoring the Impact of COVID-19 on the Pharmaceutical Market.. Title of subordinate document 2021. Available from: https:// www.iqvia.com/library/white- papers/monitoring-the-impact-ofcovid-19-on-the-pharmaceutical-market-eu5
[27]
Lange M, Joo S, Couette PA, de Jaegher S, Joly F, Humbert X. Impact on mental health of the COVID-19 outbreak among community pharmacists during the sanitary lockdown period. Ann Pharm Fr 2020; 78(6): 459-63.
[http://dx.doi.org/10.1016/j.pharma.2020.09.002] [PMID: 33038309]
[28]
Cadogan CA, Hughes CM. On the frontline against COVID-19: Community pharmacists’ contribution during a public health crisis. Res Social Adm Pharm 2021; 17(1): 2032-5.
[http://dx.doi.org/10.1016/j.sapharm.2020.03.015] [PMID: 32245691]
[29]
Ali M, Schifano F, Robinson P, et al. Impact of community pharmacy diabetes monitoring and education programme on diabetes management: A randomized controlled study. Diabet Med 2012; 29(9): e326-33.
[http://dx.doi.org/10.1111/j.1464-5491.2012.03725.x] [PMID: 22672148]
[30]
Lum ZK, Siaw MYL, Lee MJX, et al. Impact of pharmaceutical care on mental well-being and perceived health among community-dwelling individuals with type 2 diabetes. Qual Life Res 2019; 28(12): 3273-9.
[http://dx.doi.org/10.1007/s11136-019-02253-2] [PMID: 31359238]
[31]
Olesen C, Harbig P, Buus KM, Barat I, Damsgaard EM. Impact of pharmaceutical care on adherence, hospitalisations and mortality in elderly patients. Int J Clin Pharm 2014; 36(1): 163-71.
[http://dx.doi.org/10.1007/s11096-013-9898-1] [PMID: 24293339]
[32]
MacKeigan LD, Nissen LM. Clinical pharmacy services in the home. Dis Manag Health Outcomes 2008; 16: 227-44.
[http://dx.doi.org/10.2165/00115677-200816040-00004]
[33]
Desplenter FAM, Simoens S, Laekeman G. The impact of informing psychiatric patients about their medication: A systematic review. Pharm World Sci 2006; 28(6): 329-41.
[http://dx.doi.org/10.1007/s11096-006-9054-2] [PMID: 17216295]
[34]
Lépine JP, Gastpar M, Mendlewicz J, Tylee A. Depression in the community: The first pan-European study DEPRES (Depression research in European society). Int Clin Psychopharmacol 1997; 12(1): 19-29.
[http://dx.doi.org/10.1097/00004850-199701000-00003] [PMID: 9179630]
[35]
Kalita J, Tripathi A, Dongre N, Misra UK. Impact of COVID-19 pandemic and lockdown in a cohort of myasthenia gravis patients in India. Clin Neurol Neurosurg 2021; 202(202): 106488.
[http://dx.doi.org/10.1016/j.clineuro.2021.106488] [PMID: 33460984]
[36]
Liu S, Luo P, Tang M, et al. Providing pharmacy services during the coronavirus pandemic. Int J Clin Pharm 2020; 42(2): 299-304.
[http://dx.doi.org/10.1007/s11096-020-01017-0] [PMID: 32222911]
[37]
Singh G, Sharma PK, Malviya R, Awasthi R. Novel corona virus (COVID-19) disease and ophthalmic manifestations: Clinical evidences. Dermatol Ther 2020; 33(6): e13814.
[http://dx.doi.org/10.1111/dth.13814] [PMID: 32526073]
[38]
Sharma A, Malviya R, Kumar V, Gupta R, Awasthi R. Severity and risk of COVID-19 in cancer patients: An evidence-based learning. Dermatol Ther 2020; 33(5): e13778.
[http://dx.doi.org/10.1111/dth.13778] [PMID: 32515033]

Rights & Permissions Print Cite
Article Metrics
40
1
© 2024 Bentham Science Publishers | Privacy Policy